What is not working for the company?
What is working for the company?
|Name||Sep 22||Jun 22|
|Mutual Funds (Change:0.00)||0%||0%|
|Insurance Companies (Change:0.00)||0%||0%|
|Other DIIs (Change:0.00)||0%||0%|
|Non Institution (Change:0.00)||29.42%||29.42%|
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in ANUH PHARMA LTD.
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
Frequently Asked Questions
What is the Share price of ANUH PHARMA LTD. (ANUHPHR)?
Can I buy ANUH PHARMA LTD. (ANUHPHR) shares?
How do I buy ANUH PHARMA LTD. (ANUHPHR) from Angel One?
- Direct investment: You can buy ANUH PHARMA LTD. (ANUHPHR) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to ANUH PHARMA LTD. (ANUHPHR) shares.
In which sector do ANUH PHARMA LTD. (ANUHPHR) belong?
Today's live share price for ANUH PHARMA LTD. is NSE: N/A, BSE: ₹ 91.30 with a current market capitalization of .
Anuh Pharma Ltd is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company offers bulk drugs and chemicals. Their products are antibiotics, erythromycin salts, chloramphenicol and other chemicals. The company is part of the SK Group. Anuh Pharma Ltd was incorporated on February 19, 1960. The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra. All the facilities are built and operated according to cGMP. They also received plant approvals from several MNCs. The business headquarters of the firm is located in the commercial capital of India, Mumbai. The company is a recognized export house and exports their products to Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore and several other countries. During the year 2006-07, the company commissioned the new plant with all latest modern techniques and facilities. Thus, the production capacity of Antibiotics increased from 400,000 Kg to 600,000 Kg. During the year 2008-09, the company completed the on-going expansion of their plant, thus they increased the installed capacity by 150 MT per annum. In September 2008, they expanded unit started commercial production. In January 2010, the company received approval for their product Erythromycin E.P. from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Erythromycin E.P. in European counties for their own consumption. In April 2010, the company received approval for their product Pyrazinamide from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Pyrazinamide in European countries for their own consumption. In June 2010, the company received approval for their product Clobetasol Propionate from European Directorate for the Quality Medicines & Healthcare. This approval paves the way for the company to sell Clobetasol Propionate in European counties for their own consumption.Read more